CoChat

Impact of technology on glycaemic control in type 2 diabetes: A meta‐analysis of randomized trials on continuous glucose monitoring and continuous subcutaneous insulin infusion

Dicembrini, Ilaria, Mannucci, Edoardo, Monami, Matteo, Pala, Laura · 2019 · Diabetes, Obesity and Metabolism
Cited by 46

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Aim: To conduct a meta‐analysis to assess the effect of continuous subcutaneous insulin infusion (CSII), continuous glucose monitoring (CGM), and the combination of the two, on glycaemic control in type 2 diabetes. Materials and methods: The analysis included randomized clinical trials comparing CSII with multiple daily injections (MDI) in people with type 2 diabetes, as well as studies comparing CGM or flash glucose monitoring (FGM) with self‐monitoring of blood glucose (SMBG), with a duration of at least 12 weeks, identified in Medline or clinicaltrials.gov . The principal endpoint was glycated haemoglobin (HbA1c) at the end of the trial. Mean and 95% confidence intervals (CIs) for HbA1c and Mantel–Haenzel odds ratios for severe hypoglycaemia were calculated, using random‐effect models. Results: The retrieved trials showed a significant heterogeneity (I 2 = 90%). The difference in HbA1c between CSII and MDI was not statistically significant (−0.26% [95% CI –0.74;0.22]; P = .29). The difference in endpoint HbA1c between CGM and SMBG was marginally significant (−0.24 [95% CI –0.49;0.00]; P = .05), and CGM was possibly associated with a lower hypoglycaemic risk. Only one trial explored the effect of FGM, as compared with SMBG, on HbA1c in type 2 diabetes, finding no difference across groups (at study end: 8.4% ± 0.8% vs 8.3% ± 1.1% with FGM and SMBG, respectively). Conversely, FGM was associated with an improvement in quality of life and with a lower incidence of hypoglycaemic events. The small number of retrieved trials indicates that the results should be interpreted with caution. Conclusions: The analysis showed that CSII, CGM and FGM provide only small benefits compared with MDI (on either HbA1c, hypoglycaemic risk or quality of life) in insulin‐treated people with type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.13845

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 46

Metadata

Authors
Dicembrini, I., Mannucci, E., Monami, M., & Pala, L.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2019-09-13
Volume
21
Issue
12
Pages
2619-2625
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2965160656
Cited by
46
References
8
FWCI
4.30
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of technology on glycaemic control in type 2 diabetes: A meta‐analysis of randomized trials on continuous glucose monitoring and continuous subcutaneous insulin infusion. https://app.cochat.ai/papers/10.1111/dom.13845
The paper
Dicembrini, I., Mannucci, E., Monami, M., & Pala, L. (2019). Impact of technology on glycaemic control in type 2 diabetes: A meta‐analysis of randomized trials on continuous glucose monitoring and continuous subcutaneous insulin infusion. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13845

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.